Prosecution Insights
Prosecution Insights
Listed by the USPTO as PIHONAK, SARAH
Tech Center 1600 • Art Units: 1617 1627
This examiner grants 61% of resolved cases
Sarah Pihonak is an examiner in Tech Center 1600 and Art Unit 1617. The examiner has a high volume of 1510 resolved cases and an allowance rate of 61.3 percent. This indicates a moderate but consistent likelihood of success. The median days to allowance is 1028, which provides a timeline for the expected duration of prosecution. With 1510 resolved cases, the data is very robust.
The interview lift for this examiner is 42.6 percent. This is an exceptionally high lift, suggesting that interviews are a critical factor in achieving an allowance compared to the 61.3 percent baseline. Practitioners should make interviews a primary strategy to take advantage of the 42.6 percent increase in success probability. The 1028 median days to allowance is a key factor for planning in Art Unit 1617. Overall, the 61.3 percent allowance rate and the 42.6 percent interview lift suggest that proactive engagement is highly effective across the 1510 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579786 | COMPOSITIONS COMPRISING CONSTITUENTS, DERIVATIVES OR EXTRACTS OF CANNABIS | Non-Final OA | Nicoventures Trading Limited |
| 19556454 | AMINO ACID COMPOSITIONS | Non-Final OA | ThermoLife International, LLC |
| 19556470 | AMINO ACID COMPOSITIONS | Non-Final OA | ThermoLife International, LLC |
| 19556505 | AMINO ACID COMPOSITIONS | Non-Final OA | ThermoLife International, LLC |
| 18035578 | A Method of Treating Depression by Immune Modulation | Non-Final OA | The University of British Columbia |
| 18237360 | METALLOENZYME MODULATORS | Non-Final OA | Regents of the University of Minnesota |
| 18370558 | TREATMENTS FOR BLOOD-BRAIN BARRIER DYSFUNCTION AND RECURRENT SEIZURES USING NOX/LOX/COX INHIBITORS | Final Rejection | University of Kentucky Research Foundation |
| 18265660 | Method and Composition for Treating Pulmonary Fibrosis | Final Rejection | MANNKIND CORPORATION |
| 18652776 | USE OF TRADIPITANT IN MOTION SICKNESS | Non-Final OA | Vanda Pharmaceuticals Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy61.4% of resolved applications examined by Sarah Pihonak were allowed (1,512 resolved cases), compared with 34.0% across Art Unit 1617 over the last five years.
This examiner's interview lift is +42.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sarah Pihonak took 1,028 days on average from filing to allowance.
Sarah Pihonak examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).